Brian Rini
布莱恩·里尼
MD
Professor of Medicine; Chief, Section of Hematology/Oncology医学教授；血液学/肿瘤学科主任
👥Biography 个人简介
Brian Rini is a world-leading RCC investigator who shaped modern targeted and combination immunotherapy strategies. His KEYNOTE-426 trial establishing pembrolizumab plus axitinib as a first-line RCC standard and seminal work on VEGF-pathway agents define the contemporary treatment paradigm.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Pembrolizumab + Axitinib Combination
Led KEYNOTE-426 trial showing pembrolizumab plus axitinib improved OS and PFS versus sunitinib across all risk groups in advanced RCC, establishing a new global first-line standard.
VEGF-Targeted Therapy in RCC
Conducted foundational trials of sunitinib, axitinib, and cabozantinib, defining their roles in the RCC treatment sequence and contributing to multiple FDA approvals.
Representative Works 代表性著作
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
New England Journal of Medicine (2019)
KEYNOTE-426 trial demonstrating pembro+axitinib superiority over sunitinib across all IMDC risk groups, establishing a new first-line standard for advanced RCC.
Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma
The Lancet Oncology (2011)
AXIS trial demonstrating axitinib superior PFS versus sorafenib in second-line advanced RCC, leading to FDA approval of axitinib.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Dean Bajorin
Memorial Sloan Kettering Cancer Center
Jonathan Rosenberg
Memorial Sloan Kettering Cancer Center
Thomas Powles
Barts Cancer Institute, Queen Mary University of London
Andrea Necchi
Vita-Salute San Raffaele University
关注 布莱恩·里尼 的研究动态
Follow Brian Rini's research updates
留下邮箱，当我们发布与 Brian Rini（Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment